查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1372743

基于肿瘤学的体内CRO 市场- 全球行业规模、份额、趋势、机会和预测，2018-2028 年按适应症（血癌、实体瘤）、按模型（同基因模型、患者衍生异种移植、异种移植）、按地区和竞赛

Oncology Based In-vivo CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 By Indication (Blood Cancer, Solid Tumor), By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft), By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球化学品即服务市场价值为 12.4 亿美元，预计在预测期内将大幅成长，预计复合年增长率 (CAGR) 为 8.29%，预计到 2028 年将达到 109.2 亿美元。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 12.4亿美元
2028 年市场规模 20亿美元
2023-2028 年复合年增长率 8.29%
成长最快的细分市场 实体肿瘤
最大的市场 北美洲

癌症盛行率上升

癌症发生率的不断上升推动基于肿瘤学的体内合约研究组织（CRO）市场进入了一个充满活力的成长阶段。随着癌症继续在全球范围内产生令人震惊的影响，对快速、精确的解决方案的需求不断增加，从而刺激了研究和开发活动的激增。这种激增反过来又推动了对体内 CRO 提供的专业服务的需求。随着癌症生物学和治疗方式的复杂性不断发展，製药和生物技术公司越来越依赖这些 CRO 进行复杂的临床前和临床研究。癌症研究的复杂性需要采用多学科方法，而体内 CRO 擅长提供必要的工具、专业知识和资源来加速创新疗法的开发。随着个人化医疗的发展，根据个别基因图谱客製化治疗方法需要这些 CRO 提供复杂的研究技术。此外，随着公司寻求简化营运和提高效率，将新疗法推向市场的竞争推动了外包趋势。在基因组学、成像技术和资料分析快速发展的背景下，体内 CRO 在促进突破性发现方面发挥着不可或缺的作用。最终，癌症病例的激增不仅增加了对有效治疗的需求，也成为基于肿瘤的体内CRO市场扩张和多元化的强大催化剂，将其推向战斗最前沿的关键地位对抗这种可怕的疾病。

癌症研究进展

不断发展的癌症研究格局正在对基于肿瘤学的体内合约研究组织 (CRO) 市场的成长轨迹产生深远的影响。随着我们对癌症生物学、遗传学和治疗机制理解的每一步进步，对体内 CRO 提供的高度专业化研究服务的需求激增。免疫疗法、标靶疗法和精准医学等领域的进步已经改变了肿瘤学领域，需要更复杂和量身定制的研究。体内 CRO 拥有进行与这些突破一致的复杂临床前和临床研究所需的专业知识和尖端技术。随着新的治疗途径的出现，製药和生物技术公司越来越多地求助于这些 CRO，以加快药物开发过程并确保其疗法的安全性和有效性。遗传学、肿瘤微环境和治疗反应之间错综复杂的相互作用要求采用全面、多维的研究方法，而体内 CRO 已准备好熟练地履行这一职责。此外，处于创新癌症治疗前沿的竞争动力促使公司将研究活动外包给专业合作伙伴，有助于 CRO 市场的扩张。在科学快速进步的时代，癌症研究的进步与基于肿瘤学的体内 CRO 市场的成长之间的共生关係，有望在对抗癌症的斗争中开闢一条变革性的道路。

主要市场挑战

癌症研究的复杂性

癌症研究的复杂性是阻碍基于肿瘤学的体内合约研究组织（CRO）市场成长的巨大障碍。癌症类型的多样性、复杂的遗传变异和不断发展的治疗范式带来的多方面挑战需要很少有人能够提供的专业知识水平。进行准确、全面的体内研究来反映生物体内癌症的复杂现实需要复杂的方法和设备，这可能会导致 CRO 及其客户的资源紧张。此外，需要跟上快速发展的科学发现，这又增加了一层复杂性。确保体内研究有效捕捉遗传因素、肿瘤微环境和治疗反应之间的复杂相互作用，需要采取多维方法，不仅需要尖端技术，还需要对癌症生物学的深入了解。因此，癌症研究的复杂性可能会限制专家库、增加成本和延长专案时间，从而阻碍体内 CRO 市场的成长，从而强调了该领域持续创新和合作的迫切需求。

成本高

基于肿瘤学的体内合约研究组织（CRO）服务的成本飙升对市场的扩张构成了重大障碍。进行全面的体内研究需要先进的设备、熟练的人员和大量的资源，从而导致专案成本增加。这些费用可能会阻碍规模较小的製药和生物技术公司以及预算有限的研究机构获得体内 CRO 提供的专业知识和服务。此外，高成本还可能导致服务价格上涨，可能使某些客户无法负担。这种财务压力可能会限制研发工作，减慢药物发现的步伐，并限制该行业容纳更广泛项目的能力。因此，解决高成本问题对于培养一个更容易获得和充满活力的体内肿瘤学 CRO 市场至关重要，使不同的实体能够利用所需的专业能力来促进我们对癌症的理解和治疗。

主要市场趋势

个人化医疗

个人化医疗的典范转移正在对基于肿瘤学的体内合约研究组织（CRO）市场的成长轨迹产生深远的影响。随着医学科学越来越认识到个别患者对治疗反应的独特遗传和分子特征，对高度客製化的研究和临床前研究的需求激增。体内 CRO 处于这一变革趋势的前沿，能够创建高度模仿患者遗传特征的动物模型。这些模型可以精确评估潜在的疗法，并预测其在特定患者群体中的有效性和潜在的副作用。遗传因素、肿瘤微环境和治疗反应之间错综复杂的相互作用需要细緻的研究方法，而体内 CRO 拥有执行此类研究所需的专业知识和尖端技术。为了开发对每位患者最有效且毒性最小的治疗方法，製药和生物技术公司越来越依赖体内 CRO 进行研究，以弥补临床前研究和临床试验之间的差距。随着个人化医疗的发展势头，体内 CRO 在塑造肿瘤学研究和治疗开发格局方面的战略作用变得越来越明显，巩固了它们对精准癌症护理进步的关键贡献。

数位化和数据分析

数位化和资料分析的快速整合正在对基于肿瘤学的体内合约研究组织 (CRO) 市场的成长轨迹产生变革性影响。随着癌症研究日益由资料驱动，体内 CRO 正在利用先进技术来提高研究的效率、准确性和深度。即时监测、高解析度成像和复杂的资料分析工具可以全面了解癌症生物学、治疗反应和疾病进展。这场数位革命使研究人员能够从复杂的资料集中提取有意义的见解，识别以前难以捉摸的微妙模式和相关性。配备这些功能的体内 CRO 可以全面了解潜在疗法如何在分子和细胞层面上与生物体相互作用，为药物开发过程中做出更明智的决策铺平道路。此外，数位工具的整合促进了远端监控和协作，使研究人员能够跨越地理边界进行研究。这不仅加快了研究进度，也为全球合作伙伴和客户合作打开了大门。随着肿瘤学研究对精确和数据丰富的见解的需求不断增加，善于利用数位化和资料分析的体内CRO 准备推动我们对癌症的理解的进步，并推动更有效疗法的开发，巩固其在癌症研究中的关键作用。肿瘤学研究的动态景观。

细分市场洞察

适应症见解

实体瘤领域到 2022 年将占据 47.08% 的市场份额，在基于肿瘤的体内 CRO 市场中占据主导地位，预计在未来几年将继续扩大。由于其普遍性和复杂性，实体瘤已成为基于肿瘤学的体内合约研究组织（CRO）市场的主导者。这些肿瘤的特征是具有黏性的细胞团，占癌症病例的很大一部分，从而推动了对体内 CRO 提供的专门研究服务的需求。鑑于实体肿瘤内基因突变、微环境因素和治疗反应之间错综复杂的相互作用，体内 CRO 进行的临床前研究对于评估潜在疗法至关重要。随着对实体瘤生物学和标靶治疗的理解不断进步，製药和生物技术公司越来越依赖这些 CRO 进行全面研究，为临床试验设计和决策提供资讯。体内 CRO 在创建准确的动物模型和进行复杂分析方面的专业知识与实体瘤研究的复杂性相一致，使他们成为提高我们对抗这些可怕疾病的能力的关键贡献者。

模型见解

2022年，基于肿瘤的体内CRO市场由Syngeneic细分市场主导，其收入份额最大，为70.82%。同基因模型因其在癌症研究中的特殊相关性和实用性而在基于肿瘤学的体内合约研究组织 (CRO) 市场中占据主导地位。这些模型涉及将肿瘤细胞移植到具有完整免疫系统的同一物种动物体内，从而能够研究肿瘤-免疫相互作用和免疫疗法的评估。这种方法更准确地反映了人类对肿瘤免疫反应的复杂动态。随着免疫疗法作为癌症治疗的突破性途径受到关注，製药和生物技术公司寻求在同基因模型方面具有专业知识的体内 CRO。这些 CRO 能够评估新型免疫疗法的功效和安全性、预测潜在副作用并优化治疗策略。透过密切复製人类免疫系统对肿瘤的反应，同基因模型在推进免疫疗法研究和塑造基于肿瘤学的 CRO 服务轨迹方面发挥关键作用。

区域洞察

北美地区已成为基于肿瘤的体内 CRO 市场的领导者，2022 年收入份额将达到 37%。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球基于肿瘤学的体内 CRO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依适应症（血癌、实体肿瘤）
    • 依模型分类（同基因模型、病患来源的异种移植、异种移植物）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美基于肿瘤学的体内 CRO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按型号
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲基于肿瘤学的体内 CRO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按型号
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区基于肿瘤学的体内 CRO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按型号
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲基于肿瘤学的体内 CRO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按型号
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲基于肿瘤学的体内 CRO 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按指示
    • 按型号
    • 按国家/地区
  • MEA：国家分析
    • 南非肿瘤学体内 CRO
    • 沙乌地阿拉伯肿瘤学体内 CRO
    • 阿联酋肿瘤学体内 CRO

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 治疗类型推出

第 13 章：全球基于肿瘤学的体内 CRO 市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代治疗类型的威胁

第15章：竞争格局

  • 商业概览
  • 服务内容
  • 最近的发展
  • 主要人员
  • SWOT分析
    • Charles River Laboratories, Inc.
    • ICON PLC
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific SE
    • Taconic Biosciences, Inc.
    • Crown Biosciene, Inc.
    • LabCorp
    • WuXi AppTec Co., Ltd.
    • Evotec SE
    • The Jackson Laboratory

第 16 章：策略建议

第 17 章：关于我们与免责声明

简介目录
Product Code: 16152

The Global Chemical as a Service Market, valued at USD 1.24 billion in 2022, is poised for substantial growth in the forecast period with a projected Compound Annual Growth Rate (CAGR) of 8.29%, reaching an estimated USD 10.92 billion by 2028.

Chemical management services (CMS) represent a business framework where consumers opt for chemical services rather than direct chemical procurement. CMS plays a crucial role in assisting manufacturers in streamlining and enhancing the efficiency of their chemical management processes. Various sectors benefit from the chemical-as-a-service model, including agriculture and fertilizer, water treatment and purification, metal parts cleaning, paint and coatings, industrial cleaning, industrial gases, and other related domains.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.24 Billion
Market Size 2028USD 2.00 Billion
CAGR 2023-20288.29%
Fastest Growing SegmentSolid Tumor
Largest MarketNorth America

Rising Prevalence of Cancer

The relentless rise in cancer incidence has propelled the oncology-based in vivo Contract Research Organization (CRO) market into a dynamic phase of growth. As cancer continues to exert an alarming global impact, there is an escalating demand for swift and precise solutions, spurring a surge in research and development activities. This surge, in turn, fuels the need for specialized services provided by in vivo CROs. With the intricacies of cancer biology and treatment modalities constantly evolving, pharmaceutical and biotechnology companies increasingly rely on these CROs to conduct intricate preclinical and clinical studies. The complexity of cancer research requires a multidisciplinary approach, and in vivo CROs are adept at providing the essential tools, expertise, and resources to accelerate the development of innovative therapies. As personalized medicine gains traction, tailoring treatments to individual genetic profiles necessitates sophisticated research techniques offered by these CROs. Moreover, the competition to bring novel therapies to the market drives the outsourcing trend, as companies seek to streamline operations and enhance efficiency. In a landscape characterized by rapid advancements in genomics, imaging technologies, and data analytics, in vivo CROs play an indispensable role in facilitating groundbreaking discoveries. Ultimately, the surging tide of cancer cases has not only heightened the demand for effective treatments but has also become a powerful catalyst for the expansion and diversification of the oncology based in vivo CRO market, propelling it into a pivotal position at the forefront of the fight against this formidable disease.

Advancements in Cancer Research

The ever-evolving landscape of cancer research is wielding a profound influence on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. With each stride in our understanding of cancer biology, genetics, and treatment mechanisms, the demand for highly specialized research services provided by in vivo CROs surges. Advancements in areas such as immunotherapy, targeted therapies, and precision medicine have transformed the oncology field, necessitating more intricate and tailored studies. In vivo CROs possess the expertise and cutting-edge technologies required to conduct complex preclinical and clinical investigations that align with these breakthroughs. As new avenues for treatment emerge, pharmaceutical and biotechnology companies are increasingly turning to these CROs to expedite drug development processes and ensure the safety and efficacy of their therapies. The intricate interplay between genetics, tumor microenvironments, and therapeutic responses mandates a comprehensive and multidimensional approach to research, and in vivo CROs are poised to fulfill this role adeptly. Furthermore, the competitive drive to be at the forefront of innovative cancer treatments has spurred companies to outsource research activities to specialized partners, contributing to the expansion of the CRO market. In an era characterized by rapid scientific progress, the symbiotic relationship between advancements in cancer research and the growth of the oncology based in vivo CRO market is poised to forge a transformative path forward in the fight against cancer.

Key Market Challenges

Complexity of Cancer Research

The intricate nature of cancer research stands as a formidable obstacle impeding the growth of the oncology-based in vivo Contract Research Organization (CRO) market. The multifaceted challenges posed by the diversity of cancer types, intricate genetic variations, and evolving treatment paradigms demand a level of specialized expertise that few can provide. Conducting accurate and comprehensive in vivo studies that mirror the complex reality of cancer within living organisms requires sophisticated methodologies and equipment, which can strain the resources of both CROs and their clients. Moreover, the need to keep abreast of rapidly advancing scientific discoveries adds another layer of complexity. Ensuring that in vivo studies effectively capture the intricate interplay of genetic factors, tumor microenvironments, and treatment responses necessitates a multidimensional approach that requires not only cutting-edge technologies but also a deep understanding of cancer biology. As such, the complexity of cancer research can hinder the growth of the in vivo CRO market by limiting the pool of experts, increasing costs, and elongating project timelines, thereby underscoring the critical need for sustained innovation and collaboration within the field.

High Costs

The soaring costs associated with oncology-based in vivo Contract Research Organization (CRO) services pose a significant barrier to the market's expansion. Conducting comprehensive in vivo studies demands advanced equipment, skilled personnel, and substantial resources, resulting in elevated project costs. These expenses can deter smaller pharmaceutical and biotech companies, as well as research institutions with limited budgets, from accessing the expertise and services offered by in vivo CROs. Moreover, the high costs can also lead to increased pricing for services, potentially making them unaffordable for certain clients. This financial strain can curtail research and development efforts, slow down the pace of drug discovery, and limit the industry's ability to accommodate a broader range of projects. As such, addressing the issue of high costs is pivotal for fostering a more accessible and vibrant oncology based in vivo CRO market, enabling diverse entities to harness the specialized capabilities required to advance our understanding and treatment of cancer.

Key Market Trends

Personalized Medicine

The paradigm shift towards personalized medicine is exerting a profound influence on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. As medical science increasingly recognizes the unique genetic and molecular profiles that underlie individual patients' responses to treatments, the demand for highly tailored research and preclinical studies has surged. In vivo CROs are at the forefront of this transformative trend, enabling the creation of animal models that closely mimic patients' genetic characteristics. These models allow for precise evaluations of potential therapies, predicting their effectiveness and potential side effects in specific patient populations. The intricate interplay between genetic factors, tumor microenvironments, and treatment responses necessitates nuanced research methodologies, and in vivo CROs possess the expertise and cutting-edge technologies required to execute such studies. With the goal of developing treatments that are optimally effective and minimally toxic for each patient, pharmaceutical and biotech companies are increasingly relying on in vivo CROs to conduct studies that bridge the gap between preclinical research and clinical trials. As personalized medicine gains momentum, the strategic role of in vivo CROs in shaping the landscape of oncology research and therapy development becomes ever more pronounced, solidifying their pivotal contribution to the advancement of precision cancer care.

Digitalization and Data Analytics

The rapid integration of digitalization and data analytics is wielding a transformative impact on the growth trajectory of the oncology-based in vivo Contract Research Organization (CRO) market. As cancer research becomes increasingly data driven, in vivo CROs are leveraging advanced technologies to enhance the efficiency, accuracy, and depth of their studies. Real-time monitoring, high-resolution imaging, and sophisticated data analysis tools enable a comprehensive understanding of cancer biology, treatment responses, and disease progression. This digital revolution empowers researchers to extract meaningful insights from complex datasets, identifying subtle patterns and correlations that were previously elusive. In vivo CROs equipped with these capabilities can offer a comprehensive view of how potential therapies interact with living organisms at molecular and cellular levels, paving the way for more informed decision-making during drug development. Additionally, the integration of digital tools facilitates remote monitoring and collaboration, allowing researchers to conduct studies across geographical boundaries. This not only accelerates research timelines but also opens doors to global partnerships and client collaborations. As the demand for precise and data-rich insights in oncology research intensifies, in vivo CROs adept in harnessing digitalization and data analytics are poised to drive advancements in our understanding of cancer and propel the development of more effective therapies, solidifying their pivotal role in the dynamic landscape of oncology research.

Segmental Insights

Indication Insights

With a 47.08% market share in 2022, the solid tumors segment dominates the Oncology Based In-vivo CRO market and is predicted to continue expanding over the coming years. Solid tumors have emerged as dominant players in the oncology-based in vivo Contract Research Organization (CRO) market due to their prevalence and complex nature. These tumors, characterized by their cohesive mass of cells, represent a significant portion of cancer cases, driving the demand for specialized research services provided by in vivo CROs. Given the intricate interplay of genetic mutations, microenvironmental factors, and treatment responses within solid tumors, preclinical studies conducted by in vivo CROs are essential for evaluating potential therapies. As the understanding of solid tumor biology and targeted therapies advances, pharmaceutical and biotech companies increasingly rely on these CROs to conduct comprehensive studies that inform clinical trial design and decision-making. The specialized expertise of in vivo CROs in creating accurate animal models and conducting sophisticated analyses aligns with the intricacies of solid tumor research, establishing them as pivotal contributors in advancing our ability to combat these formidable diseases.

Model Insights

In 2022, the Oncology Based In-vivo CRO market was dominated by the Syngeneic segment, which held the largest revenue share of 70.82%. Syngeneic models have surged to dominance in the oncology-based in vivo Contract Research Organization (CRO) market due to their exceptional relevance and utility in cancer research. These models involve transplanting tumor cells into animals with intact immune systems from the same species, enabling the study of tumor-immune interactions and the evaluation of immunotherapies. This approach more accurately mirrors the complex dynamics of human immune responses to tumors. As immunotherapy gains traction as a groundbreaking avenue for cancer treatment, pharmaceutical and biotech companies seek in vivo CROs with specialized expertise in syngeneic models. These CROs offer the capacity to assess the efficacy and safety of novel immunotherapies, predict potential side effects, and optimize treatment strategies. By closely replicating the human immune system's responses to tumors, syngeneic models are playing a pivotal role in advancing immunotherapy research and shaping the trajectory of oncology based CRO services.

Regional Insights

The North America region has established itself as the leader in the Oncology Based In-vivo CRO Market with a significant revenue share of 37% in 2022.

Key Market Players

  • Charles River Laboratories, Inc.
  • ICON PLC
  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific SE
  • Taconic Biosciences, Inc.
  • Crown Biosciene, Inc.
  • LabCorp
  • WuXi AppTec Co., Ltd.
  • Evotec SE
  • The Jackson Laboratory

Report Scope:

In this report, the Oncology Based In-vivo CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Based In-vivo CRO Market, By Indication:

  • Blood Cancer
  • Solid Tumor

Oncology Based In-vivo CRO Market, By Model:

  • Syngeneic Model
  • Patient Derived Xenograft
  • Xenograft

Oncology Based In-vivo CRO Market, By Region:

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East & Africa

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Oncology Based In-vivo CRO Market.

Available Customizations:

  • Oncology Based In-vivo CRO Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Based In-vivo CRO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Blood Cancer, Solid Tumor)
    • 5.2.2. By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. North America Oncology Based In-vivo CRO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Model
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oncology Based In-vivo CRO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Model
    • 6.3.2. Canada Oncology Based In-vivo CRO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Model
    • 6.3.3. Mexico Oncology Based In-vivo CRO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Model

7. Europe Oncology Based In-vivo CRO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Model
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oncology Based In-vivo CRO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Model
    • 7.3.2. United Kingdom Oncology Based In-vivo CRO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Model
    • 7.3.3. Italy Oncology Based In-vivo CRO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Model
    • 7.3.4. France Oncology Based In-vivo CRO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Model
    • 7.3.5. Spain Oncology Based In-vivo CRO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Model

8. Asia-Pacific Oncology Based In-vivo CRO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Model
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Oncology Based In-vivo CRO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Model
    • 8.3.2. India Oncology Based In-vivo CRO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Model
    • 8.3.3. Japan Oncology Based In-vivo CRO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Model
    • 8.3.4. South Korea Oncology Based In-vivo CRO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Model
    • 8.3.5. Australia Oncology Based In-vivo CRO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Model

9. South America Oncology Based In-vivo CRO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Model
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oncology Based In-vivo CRO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Model
    • 9.3.2. Argentina Oncology Based In-vivo CRO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Model
    • 9.3.3. Colombia Oncology Based In-vivo CRO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Model

10. Middle East and Africa Oncology Based In-vivo CRO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Model
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oncology Based In-vivo CRO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Model
    • 10.3.2. Saudi Arabia Oncology Based In-vivo CRO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Model
    • 10.3.3. UAE Oncology Based In-vivo CRO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Model

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Treatment Type Launches

13. Global Oncology Based In-vivo CRO Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Charles River Laboratories, Inc.
    • 15.5.2. ICON PLC
    • 15.5.3. Thermo Fisher Scientific Inc.
    • 15.5.4. Eurofins Scientific SE
    • 15.5.5. Taconic Biosciences, Inc.
    • 15.5.6. Crown Biosciene, Inc.
    • 15.5.7. LabCorp
    • 15.5.8. WuXi AppTec Co., Ltd.
    • 15.5.9. Evotec SE
    • 15.5.10. The Jackson Laboratory

16. Strategic Recommendations

17. About Us & Disclaimer